Monitoring is a critical component of every clinical trial. Ensuring that collected data are accurate, consistent, and verifiable means guaranteeing both patient safety and scientific validity.
In recent years, a more efficient and technology-driven approach has emerged alongside traditional on-site monitoring: central monitoring — a methodology that uses digital systems to remotely analyze and oversee trial data.
The role of monitoring in clinical trials
Monitoring ensures that a study is conducted according to the approved protocol, Good Clinical Practice (GCP), and applicable regulations.
Historically, monitoring involved periodic on-site visits to review case report forms (CRFs), patient files, and source data.
While effective, this process is resource-intensive — requiring travel, time, and manual verification across multiple sites.
What is central monitoring?
Central monitoring represents the digital evolution of this process.
It involves the remote review and analysis of clinical data through secure centralized systems.
According to the ICH E6 (R3) Good Clinical Practice Guideline, central monitoring activities are acceptable when supported by validated systems ensuring data quality, traceability, and integrity (ICH E6 R3 Guideline – EMA).
In practice, data are collected through Electronic Data Capture (EDC) systems and analyzed by data management teams and biostatisticians in real time — without the need for site visits.
Main advantages of central monitoring
Implementing central monitoring offers measurable benefits for sponsors, CROs, and investigators:
- Reduced costs and timelines: fewer on-site visits and optimized monitoring activities.
- Greater efficiency: proactive data review allows faster identification of issues.
- Early detection of anomalies and risks: digital systems highlight protocol deviations and outliers in real time.
- Higher data quality and integrity: automated checks and audit trails ensure consistency and compliance.
The European Medicines Agency (EMA) encourages the adoption of centralized and risk-based monitoring (RBM) approaches to improve resource allocation and data reliability (EMA – Reflection Paper on Risk-Based Quality Management).
Similarly, the U.S. Food and Drug Administration (FDA) supports central monitoring within its risk-based monitoring guidance as part of modern clinical trial oversight (FDA – Guidance on Risk-Based Monitoring).
Applications in clinical trials
Central monitoring is now an integral part of Risk-Based Monitoring (RBM) strategies and quality management frameworks:
- RBM implementation: resources focus on high-risk sites or data points, improving quality and efficiency.
- Centralized safety and efficacy analyses: continuous assessment enables early detection of adverse events or protocol deviations.
- Support for sponsors and CROs: provides a global view of trial performance and faster decision-making.
- Integration with EDC systems such as ACTide: enables real-time visualization, verification, and data traceability within a unified platform.
ACTide’s role in central monitoring
ACTide, developed by Nubilaria, empowers sponsors, CROs, and research centers to implement effective central and risk-based monitoring models.
Through its integrated modules — EDC, eCRF, Designer, and RBM dashboards — ACTide allows teams to:
- automate alerts for data inconsistencies,
- perform centralized trend and deviation analyses,
- generate monitoring reports and key performance indicators (KPIs),
- ensure full GCP and regulatory compliance.
By combining automation, transparency, and data security, ACTide helps research teams improve efficiency and ensure the integrity of every data point.
Discover how our platform can simplify your monitoring activities and ensure full compliance.
Redefining quality in clinical research
Central monitoring is no longer an innovation — it’s the new standard for data quality assurance in clinical research.
It enables proactive oversight, faster decisions, and higher confidence in trial outcomes.
Discover how ACTide can support your central monitoring strategy and enhance data integrity in your next clinical trial